|
|
|
|
F-043 / F-043-1ML updated item number format
Flubromazepam
1.0 mg/mL in Methanol | Certified Reference Material
|
|
Flubromazepam is a potent, long-acting novel psychoactive benzodiazepine with anxiolytic, anticonvulsant, muscle relaxant and hypnotic properties. Flubromazepam reportedly has a high addiction potential and risk of overdose. This certified Snap-N-Spike® solution is suitable for use as a starting material in calibrators and controls for numerous GC/MS or LC/MS applications in forensic analysis, clinical toxicology and urine drug testing.
|
|
|
|
|
| Concentration:
|
1.0 mg/mL
|
| Solvent:
|
Methanol
|
| Unit Size:
|
1 ml/ampoule
|
| CAS Number:
|
2647-50-9
|
| Chemical Formula:
|
C15H10BrFN2O
|
| Molecular Weight:
|
333.16
|
| Certificate of Analysis:
|
|
| US List Price:
|
|
|
|
|
| A-915 / A-915-1ML |
|
7-Aminoclonazepam, 100 μg/mL
|
|
$27.10
|
|
|
|
|
|
| A-916 / A-916-1ML |
|
7-Aminoclonazepam, 1.0 mg/mL
|
|
$112.00
|
|
|
|
|
|
| A-917 / A-917-1ML |
|
7-Aminoclonazepam-D4, 100 μg/mL
|
|
$46.90
|
|
|
|
|
|
| A-924 / A-924-1ML |
|
7-Aminoclonazepam-D4, 1.0 mg/mL
|
|
$462.00
|
|
|
|
|
|
| B-064 / B-064-1ML |
|
Bromazepam-D4, 100 µg/mL
|
|
$86.50
|
|
|
|
|
|
| B-903 / B-903-1ML |
|
Bromazepam, 1.0 mg/mL
|
|
$27.10
|
|
|
|
|
|
| C-905 / C-905-1ML |
|
Clonazepam-D4, 100 μg/mL
|
|
$46.90
|
|
|
|
|
|
| C-906 / C-906-1ML |
|
Clonazepam-D4, 1.0 mg/mL
|
|
$418.00
|
|
|
|
|
|
| D-902 / D-902-1ML |
|
Diazepam-D5, 100 μg/mL
|
|
$45.50
|
|
|
|
|
|
| D-907 / D-907-1ML |
|
Diazepam, 1.0 mg/mL
|
|
$28.20
|
|
|
|
|
|
| D-910 / D-910-1ML |
|
Diazepam-D5, 1.0 mg/mL
|
|
$165.00
|
|
|
|
|
|
| H-113 / H-113-1ML |
|
3-Hydroxyphenazepam, 1.0 mg/mL
|
|
$244.00
|
|
|
|
|
|
| N-903 / N-903-1ML |
|
Nordiazepam-D5, 100 μg/mL
|
|
$46.90
|
|
|
|
|
|
| N-905 / N-905-1ML |
|
Nordiazepam, 1.0 mg/mL
|
|
$38.80
|
|
|
|
|
|
| N-911 / N-911-1ML |
|
Nordiazepam-D5, 1.0 mg/mL
|
|
$181.00
|
|
|
|
|
|
| P-080 / P-080-1ML |
|
Phenazepam, 1.0 mg/mL
|
|
$218.00
|
|
|
|
|
|
| P-093 / P-093-1ML |
|
Phenazepam-D4, 100 µg/mL
|
|
$241.00
|
|
|
|
|
|
|
|
|